MA27544A1 - CHEMICALLY MODIFIED HUMAN GROWTH HORMONE CONJUGATES. - Google Patents
CHEMICALLY MODIFIED HUMAN GROWTH HORMONE CONJUGATES.Info
- Publication number
- MA27544A1 MA27544A1 MA27686A MA27686A MA27544A1 MA 27544 A1 MA27544 A1 MA 27544A1 MA 27686 A MA27686 A MA 27686A MA 27686 A MA27686 A MA 27686A MA 27544 A1 MA27544 A1 MA 27544A1
- Authority
- MA
- Morocco
- Prior art keywords
- growth hormone
- human growth
- chemically modified
- modified human
- hormone conjugates
- Prior art date
Links
- 102000002265 Human Growth Hormone Human genes 0.000 title abstract 4
- 108010000521 Human Growth Hormone Proteins 0.000 title abstract 4
- 239000000854 Human Growth Hormone Substances 0.000 title abstract 4
- 239000005556 hormone Substances 0.000 abstract 1
- 229940088597 hormone Drugs 0.000 abstract 1
- 102000035118 modified proteins Human genes 0.000 abstract 1
- 108091005573 modified proteins Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 229920003169 water-soluble polymer Polymers 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/61—Growth hormone [GH], i.e. somatotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH], i.e. somatotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Endocrinology (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Abstract
Conjugués de l'hormone de croissance humaine chimiquement modifiés La présente invention décrit une hormone de croissance humaine (hGH) modifiée chimiquement par liaison de la protéine avec un polymère soluble dans l'eau. La protéine modifiée au sens de l'invention, présente une activité hGH qui dure beaucoup plus longtemps que celle de l'hormone non modifiée, ce qui permet d'en réduire la dose et la fréquence d'administration.The present invention describes a chemically modified human growth hormone (hGH) by binding of the protein with a water-soluble polymer. The modified protein within the meaning of the invention has an hGH activity which lasts much longer than that of the unmodified hormone, which makes it possible to reduce the dose and the frequency of administration.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US33190701P | 2001-11-20 | 2001-11-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA27544A1 true MA27544A1 (en) | 2005-10-03 |
Family
ID=23295870
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA27686A MA27544A1 (en) | 2001-11-20 | 2004-05-19 | CHEMICALLY MODIFIED HUMAN GROWTH HORMONE CONJUGATES. |
Country Status (25)
Country | Link |
---|---|
EP (1) | EP1453859A2 (en) |
JP (2) | JP2005525302A (en) |
KR (2) | KR20070072924A (en) |
CN (1) | CN1608079A (en) |
AP (1) | AP2004003050A0 (en) |
AU (1) | AU2002356990A1 (en) |
BR (1) | BR0214451A (en) |
CA (1) | CA2467731A1 (en) |
CO (1) | CO5580794A2 (en) |
EA (2) | EA008505B1 (en) |
EC (1) | ECSP045114A (en) |
GE (1) | GEP20063860B (en) |
HR (1) | HRP20040448A2 (en) |
HU (1) | HUP0500997A2 (en) |
IL (1) | IL162031A0 (en) |
IS (1) | IS7268A (en) |
MA (1) | MA27544A1 (en) |
MX (1) | MXPA04004809A (en) |
NO (1) | NO20042182L (en) |
OA (1) | OA13063A (en) |
PL (1) | PL374354A1 (en) |
RS (1) | RS53104A (en) |
TN (1) | TNSN04090A1 (en) |
WO (1) | WO2003044056A2 (en) |
ZA (1) | ZA200403907B (en) |
Families Citing this family (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030171285A1 (en) * | 2001-11-20 | 2003-09-11 | Finn Rory F. | Chemically-modified human growth hormone conjugates |
US6916962B2 (en) | 2001-12-11 | 2005-07-12 | Sun Bio, Inc. | Monofunctional polyethylene glycol aldehydes |
AU2002357806A1 (en) * | 2001-12-11 | 2003-06-23 | Sun Bio, Inc. | Novel monofunctional polyethylene glycol aldehydes |
US6956135B2 (en) | 2001-12-11 | 2005-10-18 | Sun Bio, Inc. | Monofunctional polyethylene glycol aldehydes |
US7041855B2 (en) | 2001-12-11 | 2006-05-09 | Sun Bio, Inc. | Monofunctional polyethylene glycol aldehydes |
PL397261A1 (en) * | 2002-01-18 | 2012-03-26 | Biogen Idec Ma Inc. | Activated polyalkylene glycol polymer, composition and pharmaceutical composition and the use thereof |
EP1591467A1 (en) * | 2002-09-09 | 2005-11-02 | Nektar Therapeutics Al, Corporation | Conjugate between a polyethylene glycol having a terminal alkanal group and a human growth hormone |
CA2498167C (en) | 2002-09-09 | 2012-03-20 | Nektar Therapeutics Al, Corporation | Water-soluble polymer alkanals |
US20040142870A1 (en) * | 2002-11-20 | 2004-07-22 | Finn Rory F. | N-terminally monopegylated human growth hormone conjugates, process for their preparation, and methods of use thereof |
US20050281778A1 (en) * | 2003-03-28 | 2005-12-22 | Myung-Ok Park | Human growth hormone conjugated with biocompatible polymer |
WO2005034988A1 (en) * | 2003-10-10 | 2005-04-21 | Novo Nordisk A/S | Long-acting molecules in sustained release formulations |
US7524813B2 (en) | 2003-10-10 | 2009-04-28 | Novo Nordisk Health Care Ag | Selectively conjugated peptides and methods of making the same |
ES2397241T3 (en) * | 2004-01-21 | 2013-03-05 | Novo Nordisk Health Care Ag | Conjugation of peptides by transglutaminase |
AU2005278903A1 (en) * | 2004-08-31 | 2006-03-09 | Pharmacia & Upjohn Company Llc | Glycerol branched polyethylene glycol human growth hormone conjugates, process for their preparation, and methods of use thereof |
CA2590462C (en) * | 2004-12-22 | 2017-02-28 | Ambrx, Inc. | Methods for expression and purification of recombinant human growth hormone |
US7385028B2 (en) | 2004-12-22 | 2008-06-10 | Ambrx, Inc | Derivatization of non-natural amino acids and polypeptides |
CA2594557C (en) | 2004-12-22 | 2016-04-26 | Ambrx, Inc. | Modified human growth hormone |
WO2006084888A2 (en) | 2005-02-10 | 2006-08-17 | Novo Nordisk A/S | C-terminally pegylated growth hormones |
CA2604222A1 (en) | 2005-04-18 | 2006-10-26 | Novo Nordisk A/S | Il-21 variants |
CA2620638A1 (en) * | 2005-08-30 | 2007-03-08 | Novo Nordisk Health Care Ag | Liquid formulations of pegylated growth hormone |
NZ567234A (en) * | 2005-11-08 | 2011-09-30 | Ambrx Inc | Accelerants for the modification of non-natural amino acids and non-natural amino acid polypeptides |
CN101448512B (en) | 2005-12-14 | 2015-11-25 | Ambrx公司 | Purposes containing alpha-non-natural amino acid and the compositions of polypeptide, the method relating to alpha-non-natural amino acid and polypeptide and alpha-non-natural amino acid and polypeptide |
CA2655188A1 (en) * | 2006-07-07 | 2008-01-10 | Novo Nordisk Health Care Ag | New protein conjugates and methods for their preparation |
CN101108895B (en) * | 2006-07-19 | 2011-10-26 | 北京键凯科技有限公司 | Polyglycol ethanal derivant and combo of medicament and the same |
CA2666426A1 (en) | 2006-10-26 | 2008-05-02 | Novo Nordisk A/S | Il-21 variants |
CL2008002399A1 (en) | 2007-08-16 | 2009-01-02 | Pharmaessentia Corp | Substantially pure conjugate having a polymeric portion, a protein portion (interferon alpha 2b) and an aliphatic binder of 1 to 10 carbon atoms, useful in the treatment of hepatitis b or c. |
RU2488598C2 (en) * | 2008-04-03 | 2013-07-27 | Биостид Джене Експрешен Тек. Ко., Лтд. | Double-stranded polyethylene glycol modified growth hormone, preparation method and use thereof |
KR101104574B1 (en) * | 2008-05-14 | 2012-01-11 | 성균관대학교산학협력단 | Human growth hormone derivative linked with polyethyleneglycol, method for the preparation thereof and pharmaceutical composition comprising the same |
WO2010014874A2 (en) * | 2008-07-31 | 2010-02-04 | Pharmaessentia Corp. | Peptide-polymer conjugates |
WO2010015668A1 (en) | 2008-08-06 | 2010-02-11 | Novo Nordisk A/S | Conjugated proteins with prolonged in vivo efficacy |
RU2409669C9 (en) * | 2008-08-18 | 2012-05-27 | ООО "Саентифик Фьючер Менеджмент" ("Scientific Future Management", "SFM") | Method for immobilising biologically active substance (bas) on carrier (versions) and bas-carrier conjugate produced by such methods |
US8492503B2 (en) * | 2008-09-11 | 2013-07-23 | Nektar Therapeutics | Polymeric alpha-hydroxy aldehyde and ketone reagents and conjugation method |
EP2389389B1 (en) | 2009-01-22 | 2015-04-15 | Novo Nordisk Health Care AG | Stable growth hormone compounds |
CN102612376A (en) | 2009-08-06 | 2012-07-25 | 诺沃-诺迪斯克保健股份有限公司 | Growth hormones with prolonged in-vivo efficacy |
ES2667025T3 (en) | 2009-12-15 | 2018-05-09 | Ascendis Pharma Endocrinology Division A/S | Dry growth hormone composition transiently bound to a polymer carrier |
CA2787890C (en) | 2010-01-22 | 2020-01-14 | Novo Nordisk Health Care Ag | Growth hormones with prolonged in-vivo efficacy |
MX338357B (en) | 2010-01-22 | 2016-04-13 | Novo Nordisk Healthcare Ag | Stable growth hormone compounds. |
EP2571896A4 (en) * | 2010-05-17 | 2014-01-08 | Cebix Inc | Pegylated c-peptide |
EP2446898A1 (en) | 2010-09-30 | 2012-05-02 | Laboratorios Del. Dr. Esteve, S.A. | Use of growth hormone to enhance the immune response in immunosuppressed patients |
EA019967B1 (en) * | 2011-12-21 | 2014-07-30 | Общество С Ограниченной Ответственностью "Форт" (Ооо "Форт") | Polyethyleneglycol covalent conjugate with human growth hormone |
CN105120887A (en) | 2013-04-05 | 2015-12-02 | 诺和诺德保健股份有限公司 | Growth hormone compound formulation |
HUE064909T2 (en) | 2014-11-06 | 2024-04-28 | Pharmaessentia Corp | Dosage regimen for pegylated interferon |
PL3220892T3 (en) | 2014-11-21 | 2022-01-31 | Ascendis Pharma Endocrinology Division A/S | Long-acting growth hormone dosage forms |
WO2016145388A1 (en) * | 2015-03-11 | 2016-09-15 | Nektar Therapeutics | Conjugates of an il-7 moiety and an polymer |
EP3351561A4 (en) | 2015-09-18 | 2019-05-15 | University of Miyazaki | Long-acting adrenomedullin derivative |
CN114539384B (en) * | 2020-11-19 | 2024-09-06 | 江苏众红生物工程创药研究院有限公司 | Pegylated long-acting growth hormone, preparation method and medical application thereof |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4179337A (en) * | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
US4904584A (en) * | 1987-12-23 | 1990-02-27 | Genetics Institute, Inc. | Site-specific homogeneous modification of polypeptides |
EP0458064B1 (en) * | 1990-05-04 | 1998-02-25 | American Cyanamid Company | Stabilization of somatotropins by modification of cysteine residues |
CA2101918A1 (en) * | 1991-03-18 | 1992-09-19 | Samuel Zalipsky | Hydrazine containing conjugates of polypeptides and glycopolypeptides with polymers |
WO1993000109A1 (en) * | 1991-06-28 | 1993-01-07 | Genentech, Inc. | Method of stimulating immune response using growth hormone |
NZ250375A (en) * | 1992-12-09 | 1995-07-26 | Ortho Pharma Corp | Peg hydrazone and peg oxime linkage forming reagents and protein derivatives |
US5824784A (en) * | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
JP3628333B2 (en) * | 1995-09-21 | 2005-03-09 | ジェネンテック インコーポレーテッド | Human growth hormone mutant |
CN1269805A (en) * | 1997-07-14 | 2000-10-11 | 博尔德生物技术公司 | Derivatives of growth hormone and related proteins |
NZ513077A (en) * | 1999-01-14 | 2004-03-26 | Bolder Biotechnology Inc | Methods for making proteins containing free cysteine residues |
DK1157037T3 (en) * | 1999-01-29 | 2003-11-24 | Hoffmann La Roche | G-CSF-conjugates |
WO2001076639A2 (en) * | 2000-04-06 | 2001-10-18 | Pharmacia Corporation | Chemically-modified myelopoietin conjugates |
EP1352062A2 (en) * | 2001-01-11 | 2003-10-15 | Maxygen Aps | Improved growth hormone molecules |
-
2002
- 2002-11-20 IL IL16203102A patent/IL162031A0/en unknown
- 2002-11-20 KR KR1020077011730A patent/KR20070072924A/en not_active Application Discontinuation
- 2002-11-20 OA OA1200400143A patent/OA13063A/en unknown
- 2002-11-20 EA EA200400565A patent/EA008505B1/en unknown
- 2002-11-20 PL PL02374354A patent/PL374354A1/en unknown
- 2002-11-20 EA EA200700431A patent/EA200700431A1/en unknown
- 2002-11-20 MX MXPA04004809A patent/MXPA04004809A/en not_active Application Discontinuation
- 2002-11-20 EP EP02803695A patent/EP1453859A2/en not_active Withdrawn
- 2002-11-20 HU HU0500997A patent/HUP0500997A2/en unknown
- 2002-11-20 RS YU53104A patent/RS53104A/en unknown
- 2002-11-20 CN CNA028259289A patent/CN1608079A/en active Pending
- 2002-11-20 AU AU2002356990A patent/AU2002356990A1/en not_active Abandoned
- 2002-11-20 AP APAP/P/2004/003050A patent/AP2004003050A0/en unknown
- 2002-11-20 JP JP2003545691A patent/JP2005525302A/en active Pending
- 2002-11-20 WO PCT/US2002/037270 patent/WO2003044056A2/en not_active Application Discontinuation
- 2002-11-20 KR KR1020047007708A patent/KR20050044858A/en active IP Right Grant
- 2002-11-20 CA CA002467731A patent/CA2467731A1/en not_active Abandoned
- 2002-11-20 GE GE5599A patent/GEP20063860B/en unknown
- 2002-11-20 BR BRPI0214451-4A patent/BR0214451A/en not_active IP Right Cessation
-
2004
- 2004-05-17 IS IS7268A patent/IS7268A/en unknown
- 2004-05-19 MA MA27686A patent/MA27544A1/en unknown
- 2004-05-20 EC EC2004005114A patent/ECSP045114A/en unknown
- 2004-05-20 HR HR20040448A patent/HRP20040448A2/en not_active Application Discontinuation
- 2004-05-20 CO CO04046633A patent/CO5580794A2/en not_active Application Discontinuation
- 2004-05-20 ZA ZA200403907A patent/ZA200403907B/en unknown
- 2004-05-20 TN TNP2004000090A patent/TNSN04090A1/en unknown
- 2004-05-26 NO NO20042182A patent/NO20042182L/en not_active Application Discontinuation
-
2006
- 2006-07-14 JP JP2006193577A patent/JP2006321808A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
EA200700431A1 (en) | 2008-02-28 |
OA13063A (en) | 2006-11-10 |
CO5580794A2 (en) | 2005-11-30 |
RS53104A (en) | 2006-10-27 |
EA008505B1 (en) | 2007-06-29 |
EA200400565A1 (en) | 2005-06-30 |
KR20050044858A (en) | 2005-05-13 |
MXPA04004809A (en) | 2004-08-11 |
JP2006321808A (en) | 2006-11-30 |
ZA200403907B (en) | 2007-12-27 |
JP2005525302A (en) | 2005-08-25 |
HRP20040448A2 (en) | 2006-02-28 |
GEP20063860B (en) | 2006-06-26 |
IL162031A0 (en) | 2005-11-20 |
BR0214451A (en) | 2006-05-30 |
TNSN04090A1 (en) | 2006-06-01 |
NO20042182L (en) | 2004-08-11 |
WO2003044056A2 (en) | 2003-05-30 |
WO2003044056A3 (en) | 2003-08-21 |
AP2004003050A0 (en) | 2004-06-30 |
EP1453859A2 (en) | 2004-09-08 |
AU2002356990A1 (en) | 2003-06-10 |
KR20070072924A (en) | 2007-07-06 |
CN1608079A (en) | 2005-04-20 |
HUP0500997A2 (en) | 2007-11-28 |
PL374354A1 (en) | 2005-10-17 |
ECSP045114A (en) | 2004-07-23 |
IS7268A (en) | 2004-05-17 |
CA2467731A1 (en) | 2003-05-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA27544A1 (en) | CHEMICALLY MODIFIED HUMAN GROWTH HORMONE CONJUGATES. | |
DK1715887T3 (en) | N-terminal Monopegylated Human Growth Hormone Conjugates, Methods for their Preparation and Use | |
WO2004050016A3 (en) | Delivery of pharmaceutical agents via the human insulin receptor | |
WO1998051325A3 (en) | Random peptides that bind to gastro-intestinal tract (git) transport receptors and related methods | |
ATE383375T1 (en) | WTI-MODIFIED PEPTIDE | |
EP2270148A3 (en) | Method for controlling the activity of immunologically functional molecule | |
BR0212522A (en) | Zinc binding ligand, insulin hexamer, aqueous insulin preparation and methods of prolonging the action of an insulin preparation and preparing a zinc binding ligand | |
NO20054440L (en) | Liquid formulations of tumor necrosis factor binding proteins | |
ATE68976T1 (en) | SOLUBILIZATION OF PROTEINS FOR PHARMACEUTICAL COMPOSITIONS. | |
SE8902638D0 (en) | STABILIZED PROTEIN OR PEPTIDE CONJUGATES | |
EA199900979A1 (en) | COMPOSITIONS OF ACTIVATED PROTEIN | |
DK1212422T3 (en) | Human CTLA-4 antibodies and their uses | |
CY1108765T1 (en) | ANTI-ErbB2 antibody treatment | |
BG104070A (en) | Chimeric protein of interleukin-6, soluble receptor/ligand, its analogues and their application | |
EE200100507A (en) | Hydroxymatairesinol for cancer prevention | |
IL205802A (en) | Immunoconjugates comprising an immunoglobulin constant region and a biologically active molecule | |
PT1171465E (en) | ANALYSIS OF A GASTRIC INHIBITOR AND THEIR USE FOR THE TREATMENT OF DIABETES | |
MXPA03007563A (en) | Increased recovery of active proteins. | |
EA200000748A1 (en) | METHOD OF INTRODUCTION OF MONOMERIAL INSULIN ANALOGUES | |
DK1146896T3 (en) | Formulations containing monodisperse hexameric acylated insulin analogues | |
HK1023513A1 (en) | Compositions comprising conjugates of stable, active, human ob protein with antibody fc chain and methods | |
BR0316716A (en) | Chemically Modified Human Growth Hormone Conjugates | |
EA200100905A1 (en) | PHARMACEUTICAL COMPOSITION CONTAINING PROTONE PUMP INHIBITORS | |
DK0981362T3 (en) | Use of GLP-2 agonists to improve the function of the upper gastrointestinal tract | |
WO2000006185A3 (en) | Methods of using lanreotide, a somatostatin analogue |